雷替曲塞联合奥沙利铂化疗在晚期食管癌中的疗效及安全性分析  

Efficacy and safety analysis of Raltitrexed combined with Oxaliplatin chemotherapy in advanced esophageal cancer

作　　者：李红 LI Hong(nd Department of Oncology of Chaoyang Central Hospital,Chaoyang 122000 Liaoning,China)

机构地区：[1]朝阳市中心医院肿瘤内二科

出　　处：《中国民康医学》2019年第21期18-20,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:探究雷替曲塞联合奥沙利铂化疗在晚期食管癌中的疗效及安全性。方法:选择120例晚期食管癌患者为研究对象,根据随机数字表法将其分为对照组与观察组各60例,对照组给予PF化疗方案(5-氟尿嘧啶+顺铂),观察组给予雷替曲塞+奥沙利铂治疗,比较两组的近期疗效、不良反应发生率、远期存活率、生存质量评分。结果:观察组的客观缓解率为63.33%,明显高于对照组的45.00%,差异有统计学意义(P<0.05)。观察组的恶心呕吐、白细胞减少、心脏毒性反应等发生率均较对照组更低,差异有统计学意义(P<0.05)。观察组的1年存活率为75.00%、2年存活率为46.67%,高于对照组的56.67%、28.33%,差异有统计学意义(P<0.05)。随访1年、2年时,观察组存活患者的生存质量各维度评分均较对照组更高,差异有统计学意义(P<0.05)。结论:雷替曲塞联合奥沙利铂用于晚期食管癌化疗中,具有良好的近期疗效,可提高远期存活率和生存质量,还可减少化疗不良反应。Objective: To study efficacy and safety of Raltitrexed combined with Platinum chemotherapy in advanced esophageal cancer. Methods: 120 patients with advanced esophageal cancer were selected as the research subjects, and they were divided into control group(n=60) and observation group(n=60) according to the random number table method. The control group received PF chemotherapy(5-Fluorouracil + Cisplatin), while the observation group received Raltitrexed + Oxaliplatin chemotherapy. The short-term efficacy, incidence of adverse reactions, long-term survival rate, and quality of life score were compared between the two groups. Results: The objective remission rate in the observation group was 63.33%, which was significantly higher than 45.00% in the control group, and the difference was statistically significant(P<0.05). The incidence of nausea and vomiting, leukopenia, and cardiac toxicity in the observation group were lower than those in the control group, and the differences were statistically significant(P<0.05). The 1-year survival rate and 2-year survival rate of the observation group were 75.00% and 46.67%, which were higher than the control group of 56.67% and 28.33%, and the differences were statistically significant(P<0.05). At 1-and 2-year follow-up, the quality of life scores of the surviving patients in the observation group were higher than those in the control group, and the differences were statistically significant(P<0.05). Conclusions: Raltitrexed combined with Oxaliplatin chemotherapy for advanced esophageal cancer has good shortterm efficacy, can improve the long-term survival rate and the quality of life, and can also reduce the adverse reactions of chemotherapy.

关 键 词：晚期食管癌 化疗 雷替曲塞 铂类 

分 类 号：R735.1[医药卫生—肿瘤]